Prostate Cancer: Pet or Predator?

Prostate cancer is reported in 63,710 cases annually with the estimated deaths at about 1,957 per year. On a more positive note, only 3% of people under 75 years old develop metastases after their diagnosis.  Unlike other cancers, prostate cancer grows slowly, and there have been cases of patients who’ve defeated this disease without therapy.

The cancer’s slow growth moved the prominent oncologist and Professor Prof. Dr. Julius Hackethal to coin the famous term “pet cancer” and subsequently warned men to avoid procuring a biopsy In case their “pet” turns into a “predator cancer”.  

A Detailed Look

It’s saddening to note that despite the therapeutic success in both conventional and holistic oncology, numerous patients are still treated aggressively. These severe therapies often leave patients with lifelong side effects such as impotence and incontinence just to name a few.

Hormone therapies are widely available but studies on their efficacy are inconclusive, and statements are often contradictory. It’s also irritating to the point of exasperation that many health groups conclude that the disease becomes incurable once it has spread to the lymph nodes, bones, or other organs.

However, we can say that this grim notion is only true when typical conventional therapies are used. We’ve had the privilege of knowing patients who’ve survived their prostate cancer even with metastasis.

What we’ve Learned

In 1999, Lothar Hirneise became the first researcher to document the data and research of Prof. Dr. Hackethal. Working with an American team, Lothar Hirneise was entirely convinced by Prof. Dr. Hackethal’s research and its successes. In addition to the evidence indicated by Prof. Dr. Hackethal’s idea that “less therapy is more” – especially for prostate cancer – we’ve also learned that treatment should not be frantic or rushed. Instead, therapeutic steps should be considered and taken in a calm, tranquil manner.

All too often, patients are rushed into various treatments prematurely without adequately assessing their long-term consequences.

Another lesson came from our patients whose PSA (Prostate-Specific Antigen) levels changed by several hundred units within a few weeks. From these cases, we learned that the possible diagnoses for prostate cancer have to be considered from an entirely different perspective.


Our Concept

Our 3E-protocol for prostate cancer starts with an in-depth examination of the diagnosis. Afterward, we will consider various potential hormone therapies and, of course, adhere to an intensive 3E-program.

In cases of metastatic prostate cancer, the 3E-program’s focus will shift towards therapies that seek to find the causes of the condition.

What We Can Offer You

1. First of all, we would recommend a conventional approach utilizing university medicine as well as a holistic examination of your current condition by a doctor familiar with both conventional and holistic medicine. Naturally, we are aware that nearly all who come to us have already received conventional counseling or therapy. Nevertheless, we would not want to exclude conventional treatments as these methods, when addressed from a different perspective, can provide insights that will be incredibly useful in the holistic therapy approach

2. Dr. Ralf Hertle will perform a microscopic analysis of your blood to better determine the necessary detoxification measures.

3. A comprehensive anamnesis (analysis of your medical history) by a holistic cancer consultant.

4. An initial diagnostic therapy session to ascertain the cause of your condition.

Only after the steps outlined above will we analyze your current situation as a team and prepare a plan best suited for you. Afterwards, we will explain this plan to you, and together we will develop a treatment program for the length of your stay in our center as well as for the next few months after you leave us.

At the core of our approach and methods are, of course, the complete 3E-Program reinforced by our extensive years of experience with prostate cancer patients.